Related by context. All words. (Click for frequent words.) 75 Azixa ™ 72 Azixa TM 70 OXi# 69 Myrexis 69 phase IIb clinical 69 HGS ETR1 69 Allovectin 7 R 68 Exelixis compounds 68 OncoVEX GM CSF 68 RGB # 68 dacetuzumab 68 PXD# 68 Perifosine 68 vascular disrupting agent 68 pertuzumab 67 FOLOTYN ® 67 oral prodrug 67 Virulizin ® 67 huC# DM4 67 KRN# 67 novel VDA molecule 67 JAK inhibitor 67 Virulizin R 67 ganetespib 67 Panzem R NCD 67 AP# [003] 67 talactoferrin 67 AEG# 67 obatoclax 66 Archexin 66 Azedra 66 valopicitabine 66 INCB# [001] 66 Xanafide 66 IRX 2 66 Allovectin 7 66 rNAPc2 66 ASONEP 66 MOZOBIL 66 HspE7 66 axitinib 66 #D#C# 65 receptor tyrosine kinase inhibitor 65 glufosfamide 65 Imprime PGG 65 ProLindac 65 investigational monoclonal antibody 65 iSONEP 65 phase IIa clinical 65 AVN# [001] 65 MAGE A3 ASCI 65 oral ridaforolimus 65 CR# vcMMAE 65 proteasome inhibitor 65 ATL# [001] 65 ZYBRESTAT 65 celgosivir 65 Traficet EN 65 registrational trial 65 mertansine 65 Phase #b/#a clinical 65 dirucotide 65 mapatumumab 65 AQ4N 65 2 methoxyestradiol 65 HuLuc# 65 Aurexis 65 evaluating tivozanib 65 Tesetaxel 65 HGS ETR2 65 Phase IIa clinical trials 65 HuMax EGFr 65 histone deacetylase HDAC inhibitor 65 MEK inhibitor 65 JAK1 65 aflibercept 64 PRT# 64 CCX# 64 humanized monoclonal antibody 64 IMGN# 64 Ceflatonin 64 NGX# 64 Amplimexon 64 bafetinib 64 TELINTRA 64 MyVax R 64 Proxinium TM 64 Bezielle 64 PEG SN# 64 FOLOTYN 64 Bicifadine 64 Allovectin 7 ® 64 ELACYT 64 HCD# [002] 64 Nexavar ® 64 Hsp# Inhibitor 64 angiogenesis inhibitor 64 XmAb# 64 lintuzumab 64 TOCOSOL Paclitaxel 64 PNP inhibitor 64 TRO# 64 Nanobody 64 CYT# potent vascular disrupting 64 forodesine HCl 64 Glufosfamide 64 perifosine 64 elagolix 64 sapacitabine 64 Voreloxin 64 TRIOLEX 64 TREANDA 64 thymalfasin 64 Palifosfamide 64 Carfilzomib 64 pralatrexate 64 Tyrima 64 AZD# 64 Tavocept 64 custirsen 64 LHRH antagonists 64 Sym# 64 Personalized Immunotherapy 64 PS# [001] 64 Cloretazine 64 Symadex 64 ThermoDox R 64 Phase 2b clinical 64 CCR9 antagonist 64 Golimumab 64 Cloretazine ® 63 MAP# 63 refractory chronic lymphocytic 63 Amrubicin 63 Tarvacin TM 63 MEK inhibitors 63 forodesine 63 otelixizumab 63 RDEA# 63 HCV protease inhibitor 63 HuMax CD4 63 ASA# 63 metaglidasen 63 neratinib 63 SinuNase 63 ELND# 63 tezampanel 63 preclinically 63 EndoTAG TM -1 63 Seliciclib 63 PEGylated interferon beta 1a 63 RG# [001] 63 Aflibercept 63 pomalidomide 63 Phase Ib 63 Catena ® 63 virus HCV protease inhibitor 63 R#/MEM # 63 Phase Ib clinical 63 IMA# 63 vosaroxin 63 alvespimycin 63 Æterna Zentaris 63 liposomal formulation 63 ALN TTR 63 MGCD# [001] 63 APOPTONE 63 NXL# 63 brostallicin 63 selective androgen receptor modulator 63 Dacogen injection 63 ENMD # 63 tiapamil 63 voreloxin 63 eniluracil 63 bevacizumab Avastin ® 63 imetelstat 63 RhuDex ® 63 PDX pralatrexate 63 tanespimycin 63 vidofludimus 63 investigational humanized monoclonal antibody 63 TELCYTA 63 Phase IIa clinical 63 Exherin TM 63 NVA# 63 polymerase inhibitors 63 CORT # 63 seliciclib 63 XL# XL# XL# XL# 63 Amigal 63 MYDICAR ® 63 SERMs 63 UPLYSO 63 CYT# 63 TYZEKA 63 IL# PE#QQR 63 PRX # 63 Serdaxin 63 darapladib 63 oral taxane 63 Omacetaxine 63 picoplatin 63 CEQ# 63 Phase 2a 63 huN# DM1 63 telbivudine 63 JAK inhibitors 63 YONDELIS 63 OMP #M# 63 Sphingomab 63 docetaxel Taxotere ® 63 Gemzar ® 63 BAY #-# 63 CA4P 63 AzaSite Plus 63 PANVAC VF 63 entinostat 63 Targretin 63 Preclinical studies 63 Atiprimod 63 Microplasmin 63 Hedgehog Pathway Inhibitor 63 Nimotuzumab 63 Alemtuzumab 62 protein kinase inhibitor 62 preclinical studies 62 class mGluR5 inhibitor 62 Insegia 62 Chemophase 62 OPAXIO 62 PARP inhibitor 62 OncoVEX 62 CD# monoclonal antibody 62 CCR5 antagonist 62 maribavir 62 elotuzumab 62 multi kinase inhibitor 62 Chrysalin 62 BRAF inhibitor 62 ixabepilone 62 nab paclitaxel 62 ANG# 62 PROMACTA 62 efficacy endpoints 62 IMiDs 62 Debio 62 R#/MEM 62 orally bioavailable 62 Daclizumab 62 Onconase 62 dexanabinol 62 Zerenex 62 orally administered inhibitor 62 tubulin inhibitor 62 Panzem R 62 Nanobody ® 62 Panitumumab 62 Romidepsin 62 EFAPROXYN 62 ALN PCS 62 ANYARA 62 Trastuzumab 62 Asentar 62 novel anticancer 62 L BLP# 62 Mipomersen 62 HSP# inhibitor 62 Entereg R 62 Solazed TM 62 Phase IIa trials 62 BRIM2 62 Phenoptin 62 favorable pharmacokinetic profile 62 cilengitide 62 dasatinib Sprycel ® 62 Onalta ™ 62 Annamycin 62 vandetanib 62 sorafenib tablets 62 plus gemcitabine 62 belinostat 62 targeted radiotherapeutic 62 triphendiol 62 JAK2 inhibitor 62 Vilazodone 62 Cetrorelix 62 XL# anticancer compounds 62 ruxolitinib 62 antibody MAb 62 OMNARIS HFA 62 vismodegib 62 antisense drug 62 ADVEXIN 62 PSN# [002] 62 cetuximab Erbitux ® 62 trastuzumab Herceptin R 62 Genasense ® oblimersen 62 Pimavanserin 62 Safinamide 62 INCB# [002] 62 Clolar ® 62 AVONEX ® 62 Phase Ib study 62 Phase 2a trial 62 Evoltra ® 62 NV1FGF 62 CYC# 62 amrubicin 62 PLK1 SNALP 62 HQK 62 dextromethorphan quinidine 62 PEGylated Fab fragment 62 catheter occlusion 62 Fx #A 62 romidepsin 62 HGS# 62 FUSILEV ® 62 Laquinimod 62 secondary efficacy endpoints 62 fosbretabulin 62 XL# [003] 62 Ceflatonin R 62 #ME# 62 Tarvacin 62 systemically administered 62 bicifadine 62 Squalamine 62 erlotinib Tarceva ® 62 confirmatory Phase III 62 Fludara ® 62 GRN# 62 Troxatyl 62 ZEVALIN ® 62 polymerase inhibitor 62 AVE# 62 lintuzumab SGN 62 MGCD# [002] 62 Cethromycin 62 EOquin TM 62 Phase #b/#a trial 62 PKC# 62 eltrombopag 62 tezampanel NGX# 62 anti leukemic 62 Phase 2b study 62 PDE4 inhibitor 62 ADVEXIN clinical 62 Solazed ™ 62 glucokinase activator 62 Phase 2a clinical 62 Myrexis Inc. 62 ZFP Therapeutic 62 Cloretazine R 62 biologic therapy 62 Phase 1b 62 Akt inhibitor 61 refractory gout 61 Phase 2b Clinical Trial 61 EPC# 61 Apoptone 61 DXL# 61 Dapagliflozin 61 EOquin 61 Talactoferrin 61 REOLYSIN ® 61 ponatinib 61 limiting toxicity 61 ACTEMRA 61 Cloretazine R VNP#M 61 LymphoStat B 61 TLK# 61 Alocrest 61 mocetinostat MGCD# 61 refractory AML 61 Intravenous CP 61 sodium thiosulfate STS 61 velafermin 61 dimebon 61 HepeX B 61 kinase inhibitor 61 trodusquemine 61 trial evaluating PRX# 61 atacicept 61 ocular formulation 61 MAXY alpha 61 Besivance 61 TKM ApoB 61 mGluR5 negative 61 Albuferon TM 61 EDEMA3 61 Bortezomib 61 Epratuzumab 61 Elesclomol 61 Ofatumumab 61 lymphoma CTCL 61 Azedra TM 61 riociguat 61 MAXY G# 61 Irinotecan 61 LEP ETU 61 Clevudine 61 Viprovex TM 61 PEG Interferon lambda 61 PrevOnco 61 Panzem 61 OvaRex ® MAb 61 SinuNase TM 61 Civacir 61 ularitide 61 Phase 1b clinical 61 Marqibo 61 phase 2a 61 ridaforolimus 61 nicotinic alpha 7 61 Maribavir 61 TYKERB 61 AZILECT R 61 OHR/AVR# 61 radiation sensitizer 61 small molecule defensin 61 Taxotere ® 61 Neulasta ® 61 PRTX 61 derivatives Radilex TM 61 deforolimus 61 AeroLEF TM 61 Prodarsan ® 61 IMiDs R 61 immunomodulatory 61 nucleoside reverse transcriptase inhibitor 61 allosteric modulator NAM 61 Everolimus 61 NP2 Enkephalin 61 ALN TTR# 61 valtorcitabine 61 Vandetanib 61 CD3 monoclonal antibody 61 Zolinza 61 NEUMUNE 61 imatinib Gleevec ® 61 hepatitis C HCV 61 Campath ® 61 ospemifene 61 cancer immunotherapies 61 carfilzomib 61 preclinical 61 pseudobulbar affect PBA 61 Cethrin 61 pan HDAC inhibitor 61 cetuximab Erbitux 61 elacytarabine 61 Curaxin CBLC# 61 Hsp# inhibitor 61 HER2 positive metastatic breast 61 novel histone deacetylase 61 Cinryze TM 61 Triolex 61 PROSTVAC TM 61 anti EGFR antibody 61 fluoropyrimidine 61 Factor VIIa 61 oral proteasome inhibitor 61 Vitaxin 61 Viramidine 61 Pazopanib 61 isoform selective 61 decitabine 61 CBLC# 61 Guanilib 61 interferon gamma 1b 61 pradefovir 61 RNAi therapeutic 61 Shigamabs ® 61 cangrelor 61 trastuzumab DM1 T DM1 61 Stedivaze 61 ZOLINZA 61 generation NNRTI 61 registrational 61 sodium Injection 61 ELADUR 61 GRN#L 61 LEVADEX 61 BiTE antibody 61 vaccines oncolytic virus 61 mGluR5 NAM 61 Pivotal Phase III 61 MDV# 61 sunitinib Sutent ® 61 hypoxia activated prodrug 61 ocrelizumab 61 Sphingomab TM 61 humanized antibody 61 dacarbazine 61 Cannabinor 61 NeuroVax TM 61 MVA BN R 61 Parkinson disease levodopa induced 61 humanized anti 61 NEUGENE antisense 61 Bendavia 61 Talabostat 61 eprotirome 61 BNC# 61 GALNS 61 INCB# [003] 61 INT# [002] 61 Harbor BioSciences 61 oncology indications 61 multicenter Phase II 61 Vicinium TM 61 R sorafenib tablets 61 daclizumab 61 Phase IIb trials 61 HDAC Inhibitor 61 AZX# 61 relapsed multiple myeloma 61 Fibrillex TM 61 generation purine nucleoside 61 Phase Ib II 61 BENLYSTA ® 61 Pharmacokinetics PK 61 Thalomid ® 61 sorafenib Nexavar 60 vascular disrupting agents 60 INC# 60 phase IIb study 60 viral kinetics 60 forodesine hydrochloride 60 Arimoclomol 60 CRx 60 T DM1 60 GW# [003] 60 elvucitabine 60 regorafenib 60 Epothilones 60 Vidaza ® 60 Clavis Pharma 60 Reolysin 60 Aptivus ® 60 reslizumab 60 TG# [003] 60 Phase Ib clinical trials 60 novel topoisomerase 60 PEGylated anti 60 recurrent glioblastoma multiforme 60 Onalta 60 Azedra ™ 60 nucleoside analogues 60 FOLFOX6 chemotherapy regimen 60 Xcytrin R 60 tyrosine kinase inhibitor 60 TACI Ig 60 BrachySil ™ 60 Phase #/#a 60 elesclomol 60 Phase IIb Trial 60 vernakalant oral 60 crizotinib PF # 60 pediatric acute lymphoblastic 60 Phase IIIb clinical 60 IAP inhibitor 60 ALN VSP 60 TORISEL 60 nitazoxanide 60 torezolid phosphate 60 CRMD# 60 NPC 1C 60 KNS # 60 IgG1 monoclonal antibody 60 Bavituximab 60 laquinimod 60 hematological cancers 60 Resten NG 60 Sapacitabine 60 ACTEMRA TM 60 ProSavin 60 Phase IIb clinical trials 60 phase IIa 60 Tanespimycin 60 Elagolix 60 phase IIb 60 Genasense ® 60 inhibit metastasis 60 Valortim 60 successfully commercialize Iluvien 60 somatostatin analogue 60 Solazed 60 lorvotuzumab mertansine 60 ongoing Phase 1b 60 Hepatocellular Carcinoma HCC 60 ISENTRESS 60 Altastaph 60 Veronate 60 CD# CEA 60 Zenvia ™ 60 velafermin belinostat 60 XL# XL# XL# 60 albinterferon alfa 2b 60 Aplidin 60 TriRima 60 masitinib 60 Octreolin 60 Arikace 60 refractory Hodgkin lymphoma 60 GAP #B# 60 Corlux 60 pegylated interferons 60 MGd 60 Exelixis XL# 60 Hsp# inhibition 60 ON #.Na 60 EGFR TKI 60 HuMax CD# 60 PLX# 60 kinase inhibition 60 Ophena TM 60 synthetic retinoid 60 antitumor activity 60 unique alkylating agent 60 XP# XP# 60 NEUGENE 60 candidate CRLX# 60 IMC A# 60 bevacizumab Avastin 60 CIMZIA TM 60 VELCADE melphalan 60 sodium glucose cotransporter 60 Meets Primary Endpoint 60 Trofex 60 GVAX ® 60 temsirolimus 60 Immunotherapeutic 60 leading oral taxane 60 LBH# 60 omega interferon 60 immunotherapeutic 60 IMC #B 60 ThermoDox ® 60 targeting CD# 60 AMD# [003] 60 Restanza 60 Prestara 60 SNT MC# 60 Elotuzumab 60 peptidic compound 60 Telbivudine 60 PROCHYMAL 60 DB# [003] 60 lumiliximab 60 Dasatinib 60 MEK Inhibitor 60 initiated Phase 1b 60 EGS# 60 Panzem NCD 60 Xeloda ® 60 GAMMAGARD 60 TPI ASM8 60 docetaxel Taxotere R 60 Anticalin R 60 GMX# 60 pharmacokinetic PK 60 ANA# 60 TMC# [002] 60 immunomodulator 60 ThermoDox 60 radezolid 60 Ophena 60 Soliris TM eculizumab 60 selective modulator 60 GSK# [001] 60 Selective Electrochemical Tumor Ablation 60 tesetaxel 60 Pyridorin 60 talabostat 60 DermaVir Patch 60 Phase 1b trial 60 Satraplatin 60 HDAC inhibitor 60 PSMA ADC 60 Tezampanel 60 delafloxacin 60 HCV protease 60 BAL# [001] 60 dyskinesia PD LID 60 AEGR 60 cancer mCRC 60 SCH # 60 cannabinor 60 Marqibo TM 60 LymphoStat B TM 60 AAG geldanamycin analog 60 Randomized Phase 60 Vidaza azacitidine 60 squalamine 60 ISIS # 60 oritavancin 60 SAR# [004] 60 tafamidis 60 teriflunomide 60 samalizumab 60 Tamibarotene 60 Pralatrexate 60 ARIKACE ™ 60 HGS ETR1 mapatumumab 60 Zybrestat 60 carboplatin paclitaxel 60 anticancer therapy 60 Revimmune 60 dose limiting toxicities 60 Herceptin trastuzumab 60 personalized immunotherapy 60 BEMA TM Fentanyl 60 Vidofludimus 60 oncolytic vaccine 60 Phase #/#a trial 60 DR Cysteamine 60 FavId 60 Vectibix 60 Zoraxel 60 Canvaxin TM 60 Syncria 60 VQD 60 oral FTY# 60 chemotherapy induced neutropenia 60 androgen independent 60 calcineurin inhibitors 60 IPL# 59 Cotara 59 Ocrelizumab 59 XL# XL# 59 ICA # 59 adjuvant colon cancer 59 leukemia AML 59 TAFA# 59 anticancer agents 59 Anturol 59 Pertuzumab 59 ceftaroline 59 Ridaforolimus 59 EVIZON TM 59 Vivecon 59 oncolytic viruses 59 Pemetrexed 59 Allovectin 7 r 59 investigational compounds 59 pharmacodynamic PD 59 oxidative stress inducer 59 THR beta agonist 59 ToGA 59 regadenoson 59 alpha folate receptor 59 OvaRex R 59 mRCC 59 CTAP# Capsules 59 Aliskiren 59 trastuzumab DM1 59 anticancer compound 59 MET amplification 59 anticancer agent 59 Darinaparsin 59 NovaBay Aganocide compounds 59 CCR5 mAb 59 GSK# [002] 59 systemic RNAi therapeutic 59 OncoGel 59 SCCHN 59 iroxanadine 59 generation URAT1 inhibitor 59 YONDELIS R 59 bavituximab 59 Viprinex 59 Hsp# inhibitors 59 MKC# MT 59 SILENOR TM 59 satraplatin 59 Relivar 59 SUPPRELIN R LA 59 MGN# 59 zalutumumab 59 defensin mimetic antibiotic 59 S/GSK# 59 Lenocta TM 59 vascular disrupting 59 EDEMA4 59 T#I [002] 59 myelofibrosis polycythemia vera 59 MEND CABG II 59 oral antiviral 59 Actilon 59 CoFactor 59 Phase 2b 59 investigational pan BCR 59 VEGF Trap 59 Phase IIB 59 Angiolix 59 Phase IIb trial 59 PF # [001] 59 Telaprevir 59 ketolide antibiotic 59 CORLUX CORT # 59 cintredekin besudotox 59 gemcitabine Gemzar 59 IMiDs ® 59 Interferon alpha 59 inhibitor RG# 59 Eltrombopag 59 Acute Radiation Syndrome ARS 59 Trofex TM 59 FTY# 59 Fodosine 59 ofatumumab 59 oncolytic 59 relapsing multiple sclerosis 59 phase Ib 59 posaconazole 59 APTIVUS r 59 GLPG# 59 ara C 59 EP #R 59 IIa trial 59 drug ISA# 59 AEZS 59 investigational compound 59 non nucleoside HCV 59 SARMs 59 proteasome inhibitors 59 heavily pretreated 59 EGFR HER2 59 investigational drug 59 Pixantrone 59 MT# MEDI 59 bendamustine 59 vemurafenib 59 Lenalidomide 59 Cleviprex TM clevidipine 59 BiovaxID TM 59 dasatinib Sprycel 59 Belinostat 59 mipomersen 59 Synavive 59 IAP inhibitors 59 telaprevir VX 59 LymphoStat B belimumab 59 Ceplene 59 Advexin 59 allosteric modulator 59 Revlimid lenalidomide 59 potent anti angiogenic 59 NNR Therapeutics 59 Leukine ® 59 PI3K/Akt pathway inhibitor 59 IMiD 59 EGFR inhibitors 59 acyclovir Lauriad R 59 bardoxolone methyl 59 Combination REOLYSIN R 59 IDX# 59 hormone LHRH antagonist 59 Oracea TM 59 ENMD 59 methylnaltrexone 59 ALN RSV# 59 Lpath 59 non nucleoside inhibitor 59 peripherally acting 59 Metastatic Melanoma 59 olaparib 59 Bucindolol 59 viral kinetic 59 Aviptadil 59 eculizumab 59 SUCCEED trial 59 metastatic renal cell carcinoma 59 incyclinide 59 EpiCept NP 1 59 mTOR kinase 59 Unit Dose Budesonide 59 DACH platinum 59 Reverset 59 gefitinib Iressa 59 systemic ALCL 59 Indaflex TM 59 cell lymphoma CTCL 59 investigational immunotherapy 59 NS#/#A protease 59 Multimeric 59 tesmilifene 59 investigational protease inhibitor 59 Brentuximab Vedotin SGN 59 Vidaza R 59 oral isoform selective HDAC 59 Alzhemed TM 59 ANAVEX #-# [001] 59 liver metastases 59 bardoxolone 59 varespladib 59 palifosfamide Zymafos TM 59 blinatumomab 59 Desmoteplase 59 generation antisense 59 Tumour Vascular Disrupting Agent 59 docetaxel chemotherapy 59 rindopepimut 59 vorinostat 59 Homspera TM 59 MT#/MEDI-# 59 ApoB SNALP 59 octreotide implant 59 TRAIL receptor antibodies 59 pharmacokinetic PK study 59 evaluating picoplatin 59 LHRH antagonist 59 Phase #b/#a 59 subcutaneous formulation 59 Zalbin 59 oncolytic virus therapies 59 fluoroquinolone antibiotic 59 Phase III Trial 59 CINTREDEKIN BESUDOTOX 59 tamibarotene 59 Protexia R 59 G#DT 59 Bevacizumab 59 FGFR 59 gemcitabine chemotherapy 59 infusional 5-FU/LV 59 low dose cytarabine 59 DDP# 59 Orphan Drug Status 59 Tofacitinib 59 PD LID 59 tivozanib 59 histamine dihydrochloride 59 BiTE 59 LEUKINE 59 FOLFIRI 59 Anthim 59 Completes Patient Enrollment 59 metastatic castration resistant 59 REVLIMID lenalidomide 59 CTCE 59 Phase 2b trial 59 LibiGel ® 59 Pirfenidone 59 Torisel 59 RoACTEMRA 59 generation Hsp# inhibitor 59 EGFR expressing mCRC 59 preclinical efficacy 59 motesanib 59 plasma kallikrein inhibitor 59 DAVANAT 59 Xcytrin 59 EndoTAGTM 1 59 diabetic neuropathic pain 59 multicenter Phase 59 Radezolid 59 mTOR inhibition 59 histone deacetylase HDAC 59 ADP receptor antagonist 59 cetuximab Erbitux R 59 Tarceva TM 59 enzastaurin 58 metastatic neuroendocrine tumors 58 Delcath PHP System 58 MBP# [001] 58 TTF Therapy 58 Phase 1a clinical 58 Hepatitis C Virus HCV 58 BRIM3 58 Alpharadin 58 budesonide foam 58 Phase 2a Clinical Trial 58 TKB# 58 MCSP respectively 58 trabedersen 58 Prednisporin 58 Dicer Substrate Technology 58 tremelimumab 58 Valortim ® 58 atrasentan 58 bortezomib Velcade 58 nonclinical studies 58 recurrent NSCLC 58 milatuzumab 58 LY# [003] 58 Ambrisentan 58 CRLX# 58 antiviral activity 58 Kinase Inhibitor 58 TRX1 58 HyACT 58 BioNumerik 58 Ecallantide 58 including eniluracil ADH 58 inhibit KSP 58 TBC#